BMRN Biomarin Pharmaceutical Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BMRN

Price (delayed)

$56.5

Market cap

$10.92B

P/E Ratio

40.36

Dividend/share

N/A

EPS

$1.4

Enterprise value

$9.28B

?
Relative Growth: Rel. Growth: 61
Relative Strength: Rel. Strength: 42
Relative Valuation: Rel. Valuation: 33
Relative Profitability: Rel. Profitability: 53

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for serious and life-threatening rare and ultra-rare genetic diseases. The Company's portfolio consists of six commercialized products and ...

Highlights
BMRN's quick ratio has surged by 57% year-on-year and by 54% since the previous quarter
The revenue has grown by 10% YoY
BMRN's P/E is 77% below its 5-year quarterly average of 172.8 but 48% above its last 4 quarters average of 27.2
The debt has soared by 140% year-on-year and by 140% since the previous quarter
Biomarin Pharmaceutical's EPS has decreased by 49% YoY and by 23% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.biomarin.com
Peers: RARE CPRX ESPR

Key stats

What are the main financial stats of BMRN

BMRN stock price

How has the Biomarin Pharmaceutical stock price performed over time
Intraday
1.07%
1 week
2.5%
1 month
4.46%
1 year
4.47%
YTD
-4.93%
QTD
0.02%

Financial performance

How have Biomarin Pharmaceutical's revenue and profit performed over time
Revenue
$3.24B
Gross profit
$2.48B
Operating income
$315.23M
Net income
$268.74M
Gross margin
76.5%
Net margin
8.3%
Biomarin Pharmaceutical's operating margin has plunged by 54% YoY and by 24% from the previous quarter
The net margin has dropped by 53% year-on-year and by 23% since the previous quarter
The net income has declined by 49% year-on-year and by 23% since the previous quarter
The operating income has declined by 49% year-on-year and by 23% since the previous quarter

Price vs fundamentals

How does BMRN's price correlate with its fundamentals

Growth

What is Biomarin Pharmaceutical's growth rate over time

Valuation

What is Biomarin Pharmaceutical stock price valuation
BMRN P/E details
P/E
40.36
P/B
1.75
P/S
3.35
EV/EBIT
22.71
EV/EBITDA
19.23
EV/Sales
2.86
BMRN's P/E is 77% below its 5-year quarterly average of 172.8 but 48% above its last 4 quarters average of 27.2
Biomarin Pharmaceutical's EPS has decreased by 49% YoY and by 23% QoQ
The stock's price to book (P/B) is 42% less than its 5-year quarterly average of 3.0 and 2.8% less than its last 4 quarters average of 1.8
The equity has grown by 7% YoY and by 2.1% from the previous quarter
BMRN's price to sales (P/S) is 48% less than its 5-year quarterly average of 6.4
The revenue has grown by 10% YoY

Efficiency

How efficient is Biomarin Pharmaceutical business performance
BMRN's return on assets has dropped by 55% year-on-year and by 28% since the previous quarter
The ROE has plunged by 54% YoY and by 24% from the previous quarter
Biomarin Pharmaceutical's return on sales has decreased by 46% YoY and by 18% QoQ
Biomarin Pharmaceutical's ROIC has decreased by 42% YoY and by 18% from the previous quarter

Dividends

What is BMRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BMRN.

Financial health

How did Biomarin Pharmaceutical financials performed over time
Biomarin Pharmaceutical's total liabilities has soared by 76% YoY and by 58% from the previous quarter
BMRN's quick ratio has surged by 57% year-on-year and by 54% since the previous quarter
The debt is 77% smaller than the equity
The debt has soared by 140% year-on-year and by 140% since the previous quarter
BMRN's debt to equity has soared by 130% since the previous quarter and by 130% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.